Teva's Bid To Crack Attorney-Client Privilege Fails

Law360, New York (November 7, 2008, 12:00 AM EST) -- A federal judge has denied Teva Pharmaceuticals USA Inc.'s bid to force a Merck & Co. Inc. affiliate to produce privileged documents related to Merck's alleged fraud in obtaining the patent for allergy drug Singulair.

Judge John J. Hughes of the U.S. District Court for the District of New Jersey on Wednesday denied the motion to compel after finding Teva had failed to show Barbados-based Merck Sharp & Dohme Pharmaceuticals SRL wasn't entitled to attorney-client privilege for the information.

Teva made the request to support its...
To view the full article, register now.